查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1420998

藥物和基因輸送系統市場 - 2023-2031 年全球產業分析、規模、佔有率、數量、成長、趨勢和預測

Drug and Gene Delivery Systems Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 334 Pages | 商品交期: 2-10個工作天內

價格

藥物和基因遞送系統市場 - 報告範圍

TMR 關於全球藥物和基因遞送系統市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球藥物的收入2017-2031 年期間的基因傳遞系統市場，以2023 年為基準年，2031 年為預測年。報告中也提供了2023年至2031年全球藥物和基因遞送系統市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解藥物和基因遞送系統市場。

市場概況
2023年市場價值 34 億美元
2031 年市場價值 78 億美元
CAGR 10%

該報告深入研究了全球藥物和基因遞送系統市場的競爭格局。全球藥物和基因遞送系統市場的主要參與者已經確定，並且每個參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球藥物和基因遞送系統市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 密鑰交付系統/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：按交付系統

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按交付系統，2017-2031
    • 藥物輸送系統
      • 子宮內植入物
      • 前藥植入物
      • 聚合物藥物遞送
      • 標靶給藥
    • 基因傳遞系統
      • 病毒基因傳遞
        • 腺病毒載體
        • 慢病毒載體
        • 逆轉錄病毒載體
        • 腺相關病毒載體
        • 仙台病毒載體
        • 單純皰疹病毒載體
        • 其他
      • 非病毒基因傳遞
        • 天然有機化合物
        • 物理方法
        • 化學方法
      • 組合式混合動力系統
  • 市場吸引力分析：按交付系統

第 7 章：全球市場分析與預測：按給藥途徑

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2017-2031
    • 口服
    • 可注射
    • 吸入
    • 經皮
    • 眼睛
    • 鼻腔
    • 專題
  • 市場吸引力分析：按給藥途徑

第 8 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2017-2031
    • 傳染性疾病
    • 腫瘤學
    • 眼科
    • 泌尿科
    • 糖尿病
    • 中樞神經系統
    • 其他
  • 市場吸引力分析：按應用

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第15章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Novartis AG
    • Amgen Inc.
    • Oxford BioMedica plc.
    • SIBIONO
    • Shanghai Sunway Biotech Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Johnson & Johnson Services, Inc.
    • Becton, Dickinson and Company
    • AstraZeneca plc
    • Baxter International, Inc.
    • Boston Scientific Corporation
    • GenVivo, Inc.
Product Code: TMRGL26135

Drug and Gene Delivery Systems Market - Scope of Report

TMR's report on the global drug and gene delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug and gene delivery systems market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug and gene delivery systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug and gene delivery systems market.

Market Snapshot
Market Value in 2023US$ 3.4 Bn
Market Value in 2031US$ 7.8 Bn
CAGR10%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug and gene delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug and gene delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug and gene delivery systems market.

The report delves into the competitive landscape of the global drug and gene delivery systems market. Key players operating in the global drug and gene delivery systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug and gene delivery systems market profiled in this report.

Key Questions Answered in Global drug and gene delivery systems Market Report:

  • What is the sales/revenue generated by drug and gene delivery systems across all regions during the forecast period?
  • What are the opportunities in the global drug and gene delivery systems market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Drug and Gene Delivery Systems Market - Research Objectives and Research Approach

The comprehensive report on the global drug and gene delivery systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug and gene delivery systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug and gene delivery systems market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug and Gene Delivery Systems Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Delivery System Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Delivery System/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Delivery System, 2017-2031
    • 6.3.1. Drug Delivery Systems
      • 6.3.1.1. Intrauterine Implants
      • 6.3.1.2. Prodrug Implants
      • 6.3.1.3. Polymeric Drug Delivery
      • 6.3.1.4. Targeted Drug Delivery
    • 6.3.2. Gene Delivery Systems
      • 6.3.2.1. Viral Gene Delivery
        • 6.3.2.1.1. Adenovirus Vector
        • 6.3.2.1.2. Lentivirus Vector
        • 6.3.2.1.3. Retrovirus Vector
        • 6.3.2.1.4. Adeno-associated Virus Vector
        • 6.3.2.1.5. Sendai Virus Vector
        • 6.3.2.1.6. Herpes Simplex Virus Vector
        • 6.3.2.1.7. Others
      • 6.3.2.2. Non-viral Gene Delivery
        • 6.3.2.2.1. Natural Organic Compounds
        • 6.3.2.2.2. Physical Methods
        • 6.3.2.2.3. Chemical Methods
      • 6.3.2.3. Combined Hybrid System
  • 6.4. Market Attractiveness Analysis, by Delivery System

7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injectable
    • 7.3.3. Inhalation
    • 7.3.4. Transdermal
    • 7.3.5. Ocular
    • 7.3.6. Nasal
    • 7.3.7. Topical
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Infectious Diseases
    • 8.3.2. Oncology
    • 8.3.3. Ophthalmology
    • 8.3.4. Urology
    • 8.3.5. Diabetes
    • 8.3.6. CNS
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis, by Application

9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Delivery System, 2017-2031
    • 10.3.1. Drug Delivery Systems
      • 10.3.1.1. Intrauterine Implants
      • 10.3.1.2. Prodrug Implants
      • 10.3.1.3. Polymeric Drug Delivery
      • 10.3.1.4. Targeted Drug Delivery
    • 10.3.2. Gene Delivery Systems
      • 10.3.2.1. Viral Gene Delivery
        • 10.3.2.1.1. Adenovirus Vector
        • 10.3.2.1.2. Lentivirus Vector
        • 10.3.2.1.3. Retrovirus Vector
        • 10.3.2.1.4. Adeno-associated Virus Vector
        • 10.3.2.1.5. Sendai Virus Vector
        • 10.3.2.1.6. Herpes Simplex Virus Vector
        • 10.3.2.1.7. Others
      • 10.3.2.2. Non-viral Gene Delivery
        • 10.3.2.2.1. Natural Organic Compounds
        • 10.3.2.2.2. Physical Methods
        • 10.3.2.2.3. Chemical Methods
      • 10.3.2.3. Combined Hybrid System
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Oral
    • 10.4.2. Injectable
    • 10.4.3. Inhalation
    • 10.4.4. Transdermal
    • 10.4.5. Ocular
    • 10.4.6. Nasal
    • 10.4.7. Topical
  • 10.5. Market Value Forecast, by Application, 2017-2031
    • 10.5.1. Infectious Diseases
    • 10.5.2. Oncology
    • 10.5.3. Ophthalmology
    • 10.5.4. Urology
    • 10.5.5. Diabetes
    • 10.5.6. CNS
    • 10.5.7. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Delivery System
    • 10.7.2. By Route of Administration
    • 10.7.3. By Application
    • 10.7.4. By Country

11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Delivery System, 2017-2031
    • 11.3.1. Drug Delivery Systems
      • 11.3.1.1. Intrauterine Implants
      • 11.3.1.2. Prodrug Implants
      • 11.3.1.3. Polymeric Drug Delivery
      • 11.3.1.4. Targeted Drug Delivery
    • 11.3.2. Gene Delivery Systems
      • 11.3.2.1. Viral Gene Delivery
        • 11.3.2.1.1. Adenovirus Vector
        • 11.3.2.1.2. Lentivirus Vector
        • 11.3.2.1.3. Retrovirus Vector
        • 11.3.2.1.4. Adeno-associated Virus Vector
        • 11.3.2.1.5. Sendai Virus Vector
        • 11.3.2.1.6. Herpes Simplex Virus Vector
        • 11.3.2.1.7. Others
      • 11.3.2.2. Non-viral Gene Delivery
        • 11.3.2.2.1. Natural Organic Compounds
        • 11.3.2.2.2. Physical Methods
        • 11.3.2.2.3. Chemical Methods
      • 11.3.2.3. Combined Hybrid System
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Injectable
    • 11.4.3. Inhalation
    • 11.4.4. Transdermal
    • 11.4.5. Ocular
    • 11.4.6. Nasal
    • 11.4.7. Topical
  • 11.5. Market Value Forecast, by Application, 2017-2031
    • 11.5.1. Infectious Diseases
    • 11.5.2. Oncology
    • 11.5.3. Ophthalmology
    • 11.5.4. Urology
    • 11.5.5. Diabetes
    • 11.5.6. CNS
    • 11.5.7. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Delivery System
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Delivery System, 2017-2031
    • 12.3.1. Drug Delivery Systems
      • 12.3.1.1. Intrauterine Implants
      • 12.3.1.2. Prodrug Implants
      • 12.3.1.3. Polymeric Drug Delivery
      • 12.3.1.4. Targeted Drug Delivery
    • 12.3.2. Gene Delivery Systems
      • 12.3.2.1. Viral Gene Delivery
        • 12.3.2.1.1. Adenovirus Vector
        • 12.3.2.1.2. Lentivirus Vector
        • 12.3.2.1.3. Retrovirus Vector
        • 12.3.2.1.4. Adeno-associated Virus Vector
        • 12.3.2.1.5. Sendai Virus Vector
        • 12.3.2.1.6. Herpes Simplex Virus Vector
        • 12.3.2.1.7. Others
      • 12.3.2.2. Non-viral Gene Delivery
        • 12.3.2.2.1. Natural Organic Compounds
        • 12.3.2.2.2. Physical Methods
        • 12.3.2.2.3. Chemical Methods
      • 12.3.2.3. Combined Hybrid System
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Injectable
    • 12.4.3. Inhalation
    • 12.4.4. Transdermal
    • 12.4.5. Ocular
    • 12.4.6. Nasal
    • 12.4.7. Topical
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Infectious Diseases
    • 12.5.2. Oncology
    • 12.5.3. Ophthalmology
    • 12.5.4. Urology
    • 12.5.5. Diabetes
    • 12.5.6. CNS
    • 12.5.7. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Delivery System
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By Country/Sub-region

13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Delivery System, 2017-2031
    • 13.3.1. Drug Delivery Systems
      • 13.3.1.1. Intrauterine Implants
      • 13.3.1.2. Prodrug Implants
      • 13.3.1.3. Polymeric Drug Delivery
      • 13.3.1.4. Targeted Drug Delivery
    • 13.3.2. Gene Delivery Systems
      • 13.3.2.1. Viral Gene Delivery
        • 13.3.2.1.1. Adenovirus Vector
        • 13.3.2.1.2. Lentivirus Vector
        • 13.3.2.1.3. Retrovirus Vector
        • 13.3.2.1.4. Adeno-associated Virus Vector
        • 13.3.2.1.5. Sendai Virus Vector
        • 13.3.2.1.6. Herpes Simplex Virus Vector
        • 13.3.2.1.7. Others
      • 13.3.2.2. Non-viral Gene Delivery
        • 13.3.2.2.1. Natural Organic Compounds
        • 13.3.2.2.2. Physical Methods
        • 13.3.2.2.3. Chemical Methods
      • 13.3.2.3. Combined Hybrid System
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Injectable
    • 13.4.3. Inhalation
    • 13.4.4. Transdermal
    • 13.4.5. Ocular
    • 13.4.6. Nasal
    • 13.4.7. Topical
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Infectious Diseases
    • 13.5.2. Oncology
    • 13.5.3. Ophthalmology
    • 13.5.4. Urology
    • 13.5.5. Diabetes
    • 13.5.6. CNS
    • 13.5.7. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Delivery System
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Delivery System, 2017-2031
    • 14.3.1. Drug Delivery Systems
      • 14.3.1.1. Intrauterine Implants
      • 14.3.1.2. Prodrug Implants
      • 14.3.1.3. Polymeric Drug Delivery
      • 14.3.1.4. Targeted Drug Delivery
    • 14.3.2. Gene Delivery Systems
      • 14.3.2.1. Viral Gene Delivery
        • 14.3.2.1.1. Adenovirus Vector
        • 14.3.2.1.2. Lentivirus Vector
        • 14.3.2.1.3. Retrovirus Vector
        • 14.3.2.1.4. Adeno-associated Virus Vector
        • 14.3.2.1.5. Sendai Virus Vector
        • 14.3.2.1.6. Herpes Simplex Virus Vector
        • 14.3.2.1.7. Others
      • 14.3.2.2. Non-viral Gene Delivery
        • 14.3.2.2.1. Natural Organic Compounds
        • 14.3.2.2.2. Physical Methods
        • 14.3.2.2.3. Chemical Methods
      • 14.3.2.3. Combined Hybrid System
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Injectable
    • 14.4.3. Inhalation
    • 14.4.4. Transdermal
    • 14.4.5. Ocular
    • 14.4.6. Nasal
    • 14.4.7. Topical
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Infectious Diseases
    • 14.5.2. Oncology
    • 14.5.3. Ophthalmology
    • 14.5.4. Urology
    • 14.5.5. Diabetes
    • 14.5.6. CNS
    • 14.5.7. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Delivery System
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Delivery System Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Delivery System Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Oxford BioMedica plc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Delivery System Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. SIBIONO
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Delivery System Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Delivery System Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. F. Hoffmann-La Roche Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Delivery System Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Delivery System Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bayer AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Delivery System Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Johnson & Johnson Services, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Delivery System Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Becton, Dickinson and Company
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Delivery System Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. AstraZeneca plc
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Delivery System Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Baxter International, Inc.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Delivery System Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Boston Scientific Corporation
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Delivery System Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. GenVivo, Inc.
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Delivery System Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview

List of Tables

  • Table 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 02: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 07: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 11: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 15: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 19: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017-2031
  • Table 23: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Delivery System, 2022
  • Figure 03: Global Drug and Gene Delivery Systems Market Value Share, by Delivery System, 2022
  • Figure 04: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Drug and Gene Delivery Systems Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Application, 2022
  • Figure 07: Global Drug and Gene Delivery Systems Market Value Share, by Application, 2022
  • Figure 08: Global Drug and Gene Delivery Systems Market Value Share, by Region, 2022
  • Figure 09: Global Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 11: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 12: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 13: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 15: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 16: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 17: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 21: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 22: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 23: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 24: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 25: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26:North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Europe Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 30: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 31: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 32: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 33: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 34: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 36: Asia Pacific Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 39: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 40: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 42: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 43: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Latin America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 48: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 49: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 50: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 51: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 52: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 54: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 57: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
  • Figure 58: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 59: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
  • Figure 61: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023-2031